Cancer treatment and survivorship statistics, 2016

The number of cancer survivors continues to increase because of both advances in early detection and treatment and the aging and growth of the population. For the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborate to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results cancer registries. In addition, current treatment patterns for the most prevalent cancer types are presented based on information in the National Cancer Data Base and treatment‐related side effects are briefly described. More than 15.5 million Americans with a history of cancer were alive on January 1, 2016, and this number is projected to reach more than 20 million by January 1, 2026. The 3 most prevalent cancers are prostate (3,306,760), colon and rectum (724,690), and melanoma (614,460) among males and breast (3,560,570), uterine corpus (757,190), and colon and rectum (727,350) among females. More than one‐half (56%) of survivors were diagnosed within the past 10 years, and almost one‐half (47%) are aged 70 years or older. People with a history of cancer have unique medical and psychosocial needs that require proactive assessment and management by primary care providers. Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence‐based resources are needed to optimize care. CA Cancer J Clin 2016;66:271‐289. © 2016 American Cancer Society

[1]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[2]  A. Cherry,et al.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.

[3]  U. Ekrikpo,et al.  Increasing incidence of differentiated thyroid cancer in South East England: 1987–2006 , 2011, European Archives of Oto-Rhino-Laryngology.

[4]  L. Schover,et al.  Sexual dysfunction and infertility as late effects of cancer treatment , 2014, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[5]  E. Rivera,et al.  Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer , 2015, Cancer Chemotherapy and Pharmacology.

[6]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[7]  E. Gamelin,et al.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. , 2002, Seminars in oncology.

[8]  P. Warde,et al.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Brenner,et al.  Fear of recurrence and disease progression in long‐term (≥5 years) cancer survivors—a systematic review of quantitative studies , 2013, Psycho-oncology.

[10]  S. Edge,et al.  Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[12]  Early Breast Cancer Trialists' Collaborative Group Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[13]  R. Tuttle,et al.  Changing Trends in the Incidence of Thyroid Cancer in the United States. , 2016, JAMA otolaryngology-- head & neck surgery.

[14]  D. Kashy,et al.  Needs assessment of family caregivers of cancer survivors: three cohorts comparison , 2010, Psycho-oncology.

[15]  W. Enker,et al.  Long-term Results of Rectal Cancer Surgery with a Systematical Operative Approach , 2013, Annals of Surgical Oncology.

[16]  Y. Yamada,et al.  Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancer , 2011, Cancer.

[17]  Gustavo Werutsky,et al.  Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. , 2012, The Lancet. Oncology.

[18]  Julia H. Rowland,et al.  Mental and Physical Health–Related Quality of Life among U.S. Cancer Survivors: Population Estimates from the 2010 National Health Interview Survey , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[19]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[20]  Kassandra I. Alcaraz,et al.  Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[21]  A. Goldhirsch,et al.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  G. Andriole Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .

[23]  K. Dookeran,et al.  Racial and Ethnic Differences in Breast Cancer Survival: How Much Is Explained by Screening, Tumor Severity, Biology, Treatment, Comorbidities, and Demographics? , 2008 .

[24]  Rebecca Smith-Bindman,et al.  Racial and ethnic differences in breast cancer survival , 2008, Cancer.

[25]  P. Walsh 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, The Journal of urology.

[26]  F. Sitas,et al.  Smoking cessation after cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Conte,et al.  Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective , 2007, The breast journal.

[28]  G. Armstrong,et al.  Clinical ascertainment of health outcomes among adults treated for childhood cancer. , 2013, JAMA.

[29]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[30]  H. Kehlet,et al.  Prevalence of and factors associated with persistent pain following breast cancer surgery. , 2009, JAMA.

[31]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[32]  T. Kipps,et al.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.

[33]  L. Strobbe,et al.  Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. , 2008, The journal of pain : official journal of the American Pain Society.

[34]  P. Warde,et al.  Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy , 2013, BJU international.

[35]  R. Hays,et al.  Health‐related quality of life in older adult survivors of selected cancers: Data from the SEER‐MHOS linkage , 2015, Cancer.

[36]  A. Bleyer,et al.  Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future. , 2016, JAMA pediatrics.

[37]  C. O’Malley,et al.  Diabetes in elderly patients with breast cancer in the United States: An analysis of data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Lange,et al.  Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. , 2014, Journal of the National Cancer Institute.

[39]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[40]  R. Perera,et al.  Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. , 2013, JAMA.

[41]  M. Santoro,et al.  Central role of RET in thyroid cancer. , 2013, Cold Spring Harbor perspectives in biology.

[42]  P. Saylor,et al.  Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.

[43]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[44]  J. Moley,et al.  Medullary, anaplastic, and metastatic cancers of the thyroid. , 2010, Seminars in oncology.

[45]  Prokar Dasgupta,et al.  Recent advances in the diagnosis and treatment of bladder cancer , 2013, BMC Medicine.

[46]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[47]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[48]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2012, Journal of the National Cancer Institute.

[49]  G. Armstrong,et al.  Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study , 2014, Journal of Cancer Survivorship.

[50]  N. Parr,et al.  Long‐term changes in bone mineral density and predicted fracture risk in patients receiving androgen‐deprivation therapy for prostate cancer, with stratification of treatment based on presenting values , 2009, BJU international.

[51]  S. Sindrup,et al.  The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer , 2008, British Journal of Cancer.

[52]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[53]  H. Sasaki,et al.  Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma , 2009, BMC Cancer.

[54]  J. Griggs,et al.  Use of radioactive iodine for thyroid cancer. , 2011, JAMA.

[55]  R. Saskin,et al.  Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. , 2014, The Lancet. Oncology.

[56]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[57]  N. Keating,et al.  Receipt of locoregional therapy among young women with breast cancer , 2012, Breast Cancer Research and Treatment.

[58]  Xianglin L. Du,et al.  Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node‐positive, operable breast cancer , 2009, Cancer.

[59]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[60]  A. Tsimberidou,et al.  Richter's transformation in chronic lymphocytic leukemia. , 2006, Seminars in oncology.

[61]  A. Bleyer Young Adult Oncology: The Patients and Their Survival Challenges , 2007, CA: a cancer journal for clinicians.

[62]  I. Tumur,et al.  Treatments for chronic myeloid leukemia: a qualitative systematic review , 2012, Journal of blood medicine.

[63]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[64]  J. Tjandra,et al.  Follow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis , 2007, Diseases of the colon and rectum.

[65]  Mel Greaves,et al.  Acute lymphoblastic leukaemia , 2013, The Lancet.

[66]  I. Ganly,et al.  Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy , 2011, Cancer.

[67]  G. Armstrong,et al.  Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  R. Dellavalle,et al.  A Review of Novel Therapies for Melanoma , 2014, American Journal of Clinical Dermatology.

[69]  P. Loehrer Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2008 .

[70]  B. Coiffier,et al.  State-of-the-art therapeutics: diffuse large B-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Yu Shyr,et al.  Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.

[72]  B. Newman,et al.  Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. , 2013, The Lancet. Oncology.

[73]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[74]  E. Feuer,et al.  Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020 , 2006, Cancer Causes & Control.

[75]  Peter Baade,et al.  A systematic review of the impact of stigma and nihilism on lung cancer outcomes , 2012, BMC Cancer.

[76]  C. Audette,et al.  The sexual health of women after gynecologic malignancy. , 2010, Journal of midwifery & women's health.

[77]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[78]  N. Boissel,et al.  Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase , 2015, Journal of adolescent and young adult oncology.

[79]  E. de Azambuja,et al.  Improving quality of life after breast cancer: dealing with symptoms. , 2011, Maturitas.

[80]  David N Jr Danforth Jr,et al.  Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors , 2013 .

[81]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[82]  P. Ganz,et al.  Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[83]  E. Kimby,et al.  Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial , 2015, The Lancet.

[84]  L. V. van de Poll-Franse,et al.  Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. , 2012, European journal of cancer.

[85]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[86]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[87]  P. Mauch,et al.  Nodular lymphocyte-predominant hodgkin lymphoma. , 2007, Seminars in radiation oncology.

[88]  P. Cinciripini,et al.  Tobacco use and cessation for cancer survivors: An overview for clinicians , 2014, CA: a cancer journal for clinicians.

[89]  T. Church,et al.  Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  M. Hornbrook,et al.  Early and Late Complications Among Long-Term Colorectal Cancer Survivors With Ostomy or Anastomosis , 2010, Diseases of the colon and rectum.

[91]  S. Laurberg,et al.  Impact of bowel dysfunction on quality of life after sphincter‐preserving resection for rectal cancer , 2013, The British journal of surgery.

[92]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[93]  Andrew Ma,et al.  Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries , 2013, Annals of Surgical Oncology.

[94]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[95]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[96]  M. Graefen,et al.  Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[97]  J. Rasmussen,et al.  Recent progress in the treatment and prevention of cancer‐related lymphedema , 2015, CA: a cancer journal for clinicians.

[98]  A. Zietman,et al.  Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. , 2013, The Lancet. Oncology.

[99]  C. Orces Trends in hospitalization for fall-related injury among older adults in the United States, 1988-2005. , 2009 .

[100]  Amy Y. Chen,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[101]  A. Bleyer,et al.  The adolescence of young adult oncology. , 2009, Seminars in oncology.

[102]  S. Groshen,et al.  Long‐term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy , 2011, BJU international.

[103]  D. Rose,et al.  The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. , 2009, Journal of women's health.

[104]  R. Capocaccia,et al.  Estimation and projections of cancer prevalence from cancer registry data , 2002, Statistics in medicine.

[105]  Stacey A. Kenfield,et al.  Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  L. Harlan,et al.  Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  L. Robison,et al.  Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. , 2013, The Lancet. Oncology.

[108]  M. Leitzmann,et al.  Adiposity and risk of thyroid cancer: a systematic review and meta‐analysis , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[109]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[110]  J. Meyerhardt,et al.  Practical clinical interventions for diet, physical activity, and weight control in cancer survivors , 2015, CA: a cancer journal for clinicians.

[111]  Richard Lee,et al.  Urinary diversion after radical cystectomy for bladder cancer: options, patient selection and outcomes , 2015 .

[112]  D. Brooks,et al.  American Cancer Society Colorectal Cancer Survivorship Care Guidelines , 2015, CA: a cancer journal for clinicians.

[113]  T. Skolarus,et al.  American Cancer Society prostate cancer survivorship care guidelines , 2014, CA: a cancer journal for clinicians.

[114]  R. Huddart,et al.  Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors , 2013 .

[115]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[116]  C. Moinpour,et al.  Quality of life in long term survivors of colorectal cancer , 2002, American Journal of Gastroenterology.

[117]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[118]  S. J. LaMonte,et al.  American Cancer Society Head and Neck Cancer Survivorship Care Guideline , 2016, CA: a cancer journal for clinicians.

[119]  P. Johnstone,et al.  Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment , 2009, CA: a cancer journal for clinicians.

[120]  Elizabeth B. Habermann,et al.  Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients , 2011 .

[121]  H. Kantarjian,et al.  The biology and therapy of adult acute lymphoblastic leukemia , 2003, Cancer.

[122]  Suzanne G. Leveille,et al.  Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. , 2013, Lung cancer.

[123]  S. L. Stewart,et al.  Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. , 2011, Journal of the American Academy of Dermatology.

[124]  J. Lortet-Tieulent,et al.  Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening , 2016, CA: a cancer journal for clinicians.

[125]  Gary H Lyman,et al.  American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[127]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[128]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[129]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[130]  A. D'Amico,et al.  Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.

[131]  N. Keating,et al.  Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey. , 2016, Clinical breast cancer.

[132]  B. Hancock,et al.  Non-Hodgkin lymphoma , 2003, The Lancet.

[133]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[134]  M. Proschan,et al.  Randomized Trials of Breast-Conserving Therapy Versus Mastectomy for Primary Breast Cancer: A Pooled Analysis of Updated Results , 2005, American journal of clinical oncology.